Imbruvica(ibrutinib,依鲁替尼)为酪氨酸激酶(BTK)抑制剂,通过阻断BTK抑制肿瘤细胞的复制和转移,从而起到抗癌作用。2013年获得美国FDA批准上市。此前获批用于治疗慢性淋巴细胞白血病,Waldenstr9m氏巨球蛋白血症和边缘区淋巴瘤,并通过加速审评通道获批用于治疗套细胞淋巴瘤。2017年8月2日,美国食品药品管理局(FDA)批准其新Imbruvica适应证,用于既往接受一线或多线治疗失败的慢 Imbruvica (ibrutinib, ibrutinib) is a tyrosine kinase (BTK) inhibitor that acts as an anticancer agent by blocking BTK from inhibiting the replication and metastasis of tumor cells. In 2013, the United States FDA approved the listing. Previously approved for the treatment of chronic lymphocytic leukemia, Waldenstr9m macroglobulinemia and marginal zone lymphoma, and approved by the Accelerated Evaluation Channel for the treatment of mantle cell lymphoma. On August 2, 2017, the U.S. Food and Drug Administration (FDA) approved its new Imbruvica indications for slow past past failure of first-line or multi-line treatment